| Dr Bhupinder Singh Lyall, MD | |
|
60 Westwood Ave, Suite 314, Waterbury, CT 06708-2460 | |
| (203) 574-3007 | |
| (203) 573-1739 |
| Full Name | Dr Bhupinder Singh Lyall |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 36 Years |
| Location | 60 Westwood Ave, Waterbury, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104874999 | NPI | - | NPPES |
| 001313105 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 031310 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Mary's Hospital | Waterbury, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trinity Health Of New England Provider Network Organization Inc | 0941113567 | 621 |
News Archive
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
Researchers at the New York University Polytechnic School of Engineering have broken new ground in the development of proteins that form specialized fibers used in medicine and nanotechnology. For as long as scientists have been able to create new proteins that are capable of self-assembling into fibers, their work has taken place on the nanoscale. For the first time, this achievement has been realized on the microscale—a leap of magnitude in size that presents significant new opportunities for using engineered protein fibers.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.
A report released by Cogent Research reveals that a majority of Americans support government involvement in the distribution of direct-to-consumer genomics-based tests.
DynaVox Inc., a leading provider of software, devices and content to assist people in overcoming their speech, language or learning disabilities, announced today that its initial public offering of 9,375,000 shares of its Class A common stock has been priced at $15.00 per share. The shares are expected to begin trading tomorrow, April 22, 2010, on the NASDAQ Global Select Market under the ticker symbol "DVOX."
› Verified 7 days ago
| Entity Name | Trinity Health Of New England Provider Network Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003882812 PECOS PAC ID: 0941113567 Enrollment ID: O20031110000651 |
News Archive
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
Researchers at the New York University Polytechnic School of Engineering have broken new ground in the development of proteins that form specialized fibers used in medicine and nanotechnology. For as long as scientists have been able to create new proteins that are capable of self-assembling into fibers, their work has taken place on the nanoscale. For the first time, this achievement has been realized on the microscale—a leap of magnitude in size that presents significant new opportunities for using engineered protein fibers.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.
A report released by Cogent Research reveals that a majority of Americans support government involvement in the distribution of direct-to-consumer genomics-based tests.
DynaVox Inc., a leading provider of software, devices and content to assist people in overcoming their speech, language or learning disabilities, announced today that its initial public offering of 9,375,000 shares of its Class A common stock has been priced at $15.00 per share. The shares are expected to begin trading tomorrow, April 22, 2010, on the NASDAQ Global Select Market under the ticker symbol "DVOX."
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bhupinder Singh Lyall, MD 60 Westwood Ave, Suite 314, Waterbury, CT 06708-2460 Ph: (203) 574-3007 | Dr Bhupinder Singh Lyall, MD 60 Westwood Ave, Suite 314, Waterbury, CT 06708-2460 Ph: (203) 574-3007 |
News Archive
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
Researchers at the New York University Polytechnic School of Engineering have broken new ground in the development of proteins that form specialized fibers used in medicine and nanotechnology. For as long as scientists have been able to create new proteins that are capable of self-assembling into fibers, their work has taken place on the nanoscale. For the first time, this achievement has been realized on the microscale—a leap of magnitude in size that presents significant new opportunities for using engineered protein fibers.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.
A report released by Cogent Research reveals that a majority of Americans support government involvement in the distribution of direct-to-consumer genomics-based tests.
DynaVox Inc., a leading provider of software, devices and content to assist people in overcoming their speech, language or learning disabilities, announced today that its initial public offering of 9,375,000 shares of its Class A common stock has been priced at $15.00 per share. The shares are expected to begin trading tomorrow, April 22, 2010, on the NASDAQ Global Select Market under the ticker symbol "DVOX."
› Verified 7 days ago
Dr. Juan Fica, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1389 W Main St, Tower 2, Suite 320, Waterbury, CT 06708 Phone: 203-753-9313 Fax: 203-573-8976 | |
Mrs. Kanthimathi Jegathesan, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2271 East Main Street, Waterbury, CT 06705 Phone: 203-753-4131 Fax: 203-753-6887 | |
Robert J Mcdonald, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 170 Grandview Avenue, Waterbury, CT 06708 Phone: 203-759-3666 Fax: 203-759-3671 | |
Dr. Lydia Aoun-barakat, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 140 Grandview Ave, Suite #l01, Waterbury, CT 06708 Phone: 203-574-4187 Fax: 203-591-1453 | |
David G. Hill, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 170 Grandview Avenue, Waterbury, CT 06708 Phone: 203-759-3666 Fax: 203-759-3671 | |
Shehryar Khaliqdina, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 56 Franklin St, Waterbury, CT 06706 Phone: 203-709-8685 | |
Dr. Joseph D Scuderi, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 56 Franklin St, Waterbury, CT 06706 Phone: 203-709-6000 |